Presented at #ASCO26:
In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: https://t.co/UxXUkYwd8Z
Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer https://t.co/XgeWL3lqy6
@ASCO
We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 ๐ https://t.co/1Hnhfxr11A
GI-Coffee study. Coffee vs alvimopan for MIBC after cystectomy for bowel recovery. Great study. Worry about contamination of baseline coffee use across both arms.